graphic and cardiac enzyme analysis. Echocardiography has also been shown to be useful to risk stratify these patients by identifying or excluding wall motion abnormalities which is a marker of ischaemia. We hypothesised that THE, which enhances assessment of systolic wall thickening compared to fundamental echocardiography (FE), will result in improved risk stratifiation of acute chest pain.
Methods: Eiahtv consentina oatients with over 30 minutes of non-ST-elevation chest pain that had-lasted less than'six hours were recruited. All patients were assessed and underwent restino THE and FE scans. Diaonosis of index acute mvccardial infarction (AMI) was madebn a 24 hour creatine k&e-MB sample. Echoca;diographic images were reported by two experienced blinded observers using a 14 segment model. Patients were followed up at least 4 months after admission. Endpoints included all-cause mortality, non-fatal myocardial infarction and revascularisation procedures. anti-atherosclerotic properties in animals. To determine whether avasimibe beneficially affects the regional myocardial flow reserve (rMFR) in patients with documented or at risk for coronary artery disease (CAD). Methods: 327 patients (age 17 to 75 years; 101 female) with a rMFR (2.5 were randomized to placebo plus atorvastatin 10mg QD (atorva) or avasimibe 50 mg QD plus atorvastatin 1Omg QD (ava50, combination) or avasimibe 750 mg QD plus atorvastatin 10 mg QD (ava750, combination). PET measured myocardial blood flows at rest and during adenosine stress at baseline and at 54 weeks to determine rMFR pre and post treatment.
Results: At baseline, rMFR was similar in the three groups (1.69*0.05 SE; 1.59eO.6 and 1.57+0.06: p=NS). At 54 weeks, rMFR had improved by 0.27;tO.ll (ArMFR) for atorva, by 0.40*0.10 for ava50 and by 0.49+0.11 for ava750 combination therapy. The incremental, treatment-related ArMFR differences (over control) of 0.13 and of 0.22 between ava50 and ava750-combination and the atolva control group, while favoring avasimibe, were statistically not significant (p=O.26 and p=O.13). Defining a t 20% rMFR increase as a positive response, more patients responded to ava50 and to ava750-combination than to atorva (36% and 44%; respectively vs. 27%; p=O.Ol ava750 vs. atorva). Conclusions:
The observed trend of a greater rMFR increase in the combination than in atorva patients, though statistically not significant, together with a significantly higher incidence of positive rMFR responses in the avasimibe treatment group suggest a possible "beneficial" anti-atherosclerotic effect of avasimibe in patients with documented or at risk for CAD.
2:15 p.m. Caffeine levels were zero at baseline in all subjects and increased to 14.7 f 2 mmoll fifty minutes after caffeine intake. Rate pressure product (rest and exercise) was not affected by caffeine. Caffeine increased resting MBF significantly by 21+16% (normoxia; p<O.O005) and 35i15% (hypoxia), whereas hyperemic MBF decreased significantly by 17*18% (normoxia; p<O.O005) and 25+11% (hypoxia; p<O.O005), resulting in a decrease in CFR of 24% (normoxia) and 47% (normoxia). Conclusions: Intake of a caffeine dose equivalent to two cups of coffee significantly reduces CFR during physical exercise. This effect is even more pronounced at exposure to simulated high altitude, suggesting that caffeine may antagonize intrinsic adenosine mediated hyperemic response to exercise and hypoxia.
858-2 Caffeine Decreases
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